Truven Health MarketScan commercial claims database for Juvenile Myasthenia Gravis (JMG)

Objective: To study the trends on JMG using Truven Health MarketScan commercial claims database. Background: There are limited published studies on JMG on incidence, prevalence, morbidity, mortality, investigations and therapeutic strategies in using insurance claims database. Design/Methods: We interrogated Truven Health MarketScan commercial claims and encounter databases for JMG for male female ratio, pre-and post-pubertal, co-morbidities (pneumonia, respiratory failure, diplopia and swallowing dysfunction), procedures (thymectomy, EMG and spirometry), medication, and mortality. Results: Truven Health MarketScan Commercial Claims data, 2009–2013, identified 7,216 children 0 to 18 years old with MG diagnoses. 3,893 (53.95%) were males and 3,323 (46.05%) were females. 3109 (79.9%) males and 2,357 (70.9%) females were pre-pubescent; 784 (20.1%) males and 966 (29.1%) females were pubertal. 50 (0.7%) pneumonia, 132 (1.8%) respiratory failure, 50 (0.7%) diplopia, 116 (1.6%) swallowing dysfunction, 8 (0.1%) thymectomy, 21 (0.3%) EMG jitter block analysis, and 107 (1.5%) spirometry encounters were noted. 422 (5.8%) Pyridostigmine, 483 (6.7%) Prednisone, 93 (1.3%) Methylprednisolone, 6 IVIG treatment encounters recorded. 9 (0.1%) patients are deceased. Conclusions: Truven MarketScan Database was helpful to determine the current trends of JMG in United States; however the data is limited to commercial payers and does not include Medicare patients. Disclosure: Dr. Pochiraju has nothing to disclose. Dr. Xu has nothing to disclose. Dr. Verma has nothing to disclose.